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Abstract
Pressure overload (POL) is a classical model for studying cardiac hypertrophy,
but there has been no direct measure of hemodynamics in a conscious
ambulatory mouse model of POL. We used abdominal aortic constriction to
produce POL and radiotelemetry to measure the blood pressure and heart rate
for three weeks. The cardiac size correlated with the systolic pressure in the
last week is better than other hemodynamic parameters. Cardiac fibrosis was
more correlated to the cardiac size than to the systolic pressure. The expression
of the cardiac genes that are typically associated with cardiac hypertrophy was
correlated with both cardiac size and systolic pressure. In conclusion, the
systolic pressure is the major determinant of cardiac hypertrophy in the murine
POL model. In contrast, cardiac fibrosis shows the influence of other factors
besides systolic pressure. The combination of the POL model with continuous
direct measurements of hemodynamics represents a significant technological
advance and will lead to an extended usefulness of POL methodologically.
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Introduction
The pressure overload (POL) model was introduced to study cardiac hypertrophy as early as
the 1950s (Young et al 1950, Alexander 1953). This model, including both transverse aortic
constriction and abdominal aortic constriction, was adapted to mice and has been widely
used in cardiovascular research (Rockman et al 1991, De Windt et al 2001, Asakawa et al
2002, McMullen et al 2003, Liao et al 2004, De Acetis et al 2005, Takimoto et al 2005).
To produce the POL the aorta is commonly constricted by tying a suture against a needle to
standardize the degree of restriction. Although Rockman et al measured the carotid pressure
acutely after POL (Rockman et al 1991) and the pressure drop across the constriction at
the end of POL (Esposito et al 2002) in anesthetized mice, POL has not been monitored in
conscious ambulatory mice. Even with the same size of needles, variation in constriction
and cardiac hypertrophy can be profound (Rockman et al 1991). These differences may be
due to variations in surgical technique leading to different degrees of POL with the same
method. Monitoring the degree of POL after aortic constriction may allow for the appropriate
weighing of these variations. Cardiac fibrosis is highly associated with POL (Brede et al
2002, McMullen et al 2003, Liao et al 2004, De Acetis et al 2005), but the correlation
between fibrosis and hypertrophy or POL has not been fully investigated. Responding to POL,
hearts adapt by altering the gene expression, including embryonic, contractile or cytoskeletal,
calcium-handling, collective tissue and cardiac metabolism genes (Schoenfeld et al 1998,
Hoshijima and Chien 2002, Wagner et al 2004). It is not fully understood to what extent POL
or hypertrophy may correlate with these changes in the cardiac gene expression.
In this study, we used the state-of-the-art radiotelemetry to directly and continuously
monitor the POL-induced hemodynamic changes (including systolic, diastolic, mean arterial
pressure and heart rate) 24 h a day (Whitesall et al 2004) over 21 days during the progression
of cardiac hypertrophy after aortic constriction. We were therefore able to test the correlation
of cardiac hypertrophy and various hemodynamic consequences of aortic constriction in order
to establish the parameter that is most important in determining the degree of hypertrophy.
Further, we evaluated the extent of correlation between cardiac hypertrophy/POL and fibrosis,
and between cardiac hypertrophy/POL and cardiac gene expression.
Materials and methods
Reagents. All reagents were purchased from Sigma-Aldrich (St Louis, Missouri, USA) unless
specifically indicated.
Animals. Two months old (20–25 g) male C57Bl/6J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA), housed in a 12:12-hour light-dark cycle, fed with standard
rodent chow, and given drinking water ad libitum. The animals were cared for in accordance
with the Guide for the Care and Use of Laboratory Animals (1996, published by National
Academy Press, 2101 Constitution Ave NW, Washington, DC 20055, USA). All animal
protocols were approved by the University Committee on Use and Care of Animals of the
University of Michigan.
Pressure overload. Abdominal aortic constriction (De Windt et al 2001, Wettschureck et al
2001) was performed to induce pressure overload in mice. Briefly, the mice were anesthetized
with 2% isoflurane inhalation and midline abdominal incisions were made to expose the
abdominal aortas. Silk sutures (7–0) were used to ligate aortas against blunted needles with
different sizes, 25G, 26G or 27G. The needles were then removed immediately to restore
lumens with different stenotic aortic orifices. The abdominal cavity, muscles and skin were
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closed layer by layer with 5–0 silk sutures. For sham-operated mice, silk sutures were passed
under aortas and then removed; therefore no constrictions to aortas were performed (n = 3 for
sham and 27G groups, n = 4 for 25G and 26G groups).
Direct measurement of POL by radiotelemetry. One week after abdominal aortic constriction
or sham operation, radiotelemetry implants (PA-C20, Data Sciences International; St. Paul,
MN, USA) were placed and the pulsatile arterial pressure in the arch of the aorta and hence
POL was measured (Whitesall et al 2004). Briefly, the mice were anesthetized with 2%
isoflurane inhalation. The left common carotid was cannulated and the body of the implant
was secured in abdominal cavity. Data were collected immediately after implantations for
three weeks until the endpoint of experiments at which mice were killed for cardiac phenotypic
analyses. Average systolic pressure, diastolic pressure, mean arterial pressure (MAP) and
heart rate (HR) were obtained by averaging the data of all measured periods (2–4 weeks) or
week 4 only. The pulse pressure was calculated by subtracting the diastolic pressure from
the systolic pressure. The rate–pressure product was determined by the product of systolic
pressure and HR.
Cardiac hypertrophy estimation. Four weeks after aortic constriction or sham operation, the
cardiac size was measured as before (Duan et al 2005). Briefly, the mice were weighed and
anesthetized. The hearts were removed and ventricles were dissected for weighing. The
ventricular weight to body weight ratio (VW/BW, mg g−1) was used as an indicator of the
cardiac size. The parts of ventricles were then snap frozen in liquid nitrogen for further
analyses.
Histologic analysis. The parts of ventricles were fixed in formalin and microtome sections
were stained with hematoxylin and eosin (H&E) and Masson-trichrome (Asakawa et al 2002,
Nishida et al 2004, Duan et al 2005). Fibrosis was determined by measuring collagen staining
using NIH ImageJ 1.31V (National Institutes of Health, Bethesda, MD, USA) and expressed
as a percentage of staining (green) areas to the total areas examined.
Expression of cardiac genes. The following genes were assayed using reverse transcription
quantitative PCR (RT-QPCR) (Schoenfeld et al 1998, Duan et al 2005): type III collagen (Coll
III), atrial natriuretic peptide (ANP), α-myosin heavy chain (α-MHC), β-myosin heavy chain
(β-MHC), α-skeletal actin (Sk-Actin) and phospholamban (PLBN). SYBR green was used as
a universal fluorescent probe and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an endogenous control.
Statistical analysis. The results were analyzed using stepwise multiple regression (SPSS 15.0
from SPSS Inc., Chicago, IL, USA) or linear regression (Prism from GraphPad Software, Inc.,
San Diego, CA, USA). The correlations were considered significant if the probability values
were 0.05.
Results
Cardiac hypertrophy correlates with POL. Preliminary experiments showed more than 75%
mortality if radiotelemetry implantations were performed first or simultaneously with the
aortic constrictions. We therefore performed the aortic constrictions a week before the
implantations, which gave a less than 15% mortality. Representative 24 h pressures
(systolic, diastolic and MAP) showed that the smaller the diameter of the needle used
(tighter constriction) the greater the pressure (figure 1, table 1) and cardiac size (VW/BW)
(table 1) were. Sham group had comparable VW/BW with non-operated regular male
C57Bl/6J mice (3.79 ± 0.06 versus 3.81 ± 0.11, P > 0.05). Groups of 25G, 26G


















































































Figure 1. POL monitoring: (A) representative systolic pressure, (B) representative diastolic
pressure and (C) representative MAP of sham-operated mice and mice that underwent abdominal
aortic constriction with 25G, 26G or 27G needles. Average pressures of the week 4 were used and
graphed using 12:12-hour light-dark cycle.
and 27G all had a significantly greater VW/BW than the sham group (P < 0.01 for
all comparisons). Stepwise multiple regression analyses showed that the week-4 average
systolic pressure correlated with VW/BW better than the other hemodynamic parameters
(diastolic pressure, pulse pressure, MAP, HR and rate–pressure product) did (table 2).
More complete analyses revealed that VW/BW correlated better with pressures during
week-4 after aortic constriction than with those of all measured periods (total) (table 2).
Week-4 systolic pressure was determined as the predictor of VW/BW by stepwise multiple
regression.
The significant correlation between week-4 systolic pressure and VW/BW was further
demonstrated by a linear regression analysis (figure 2(A)). One of the three mice in the
27G group had a much smaller increase in VW/BW compared with the rest of the group
(figure 2(A), indicated by an arrow). However, its systolic pressure was also lower and was
proportional to its VW/BW (figure 2(A)), demonstrating a tight correlation. Because there
was an obvious gap between the 27G group and the other groups, we performed the linear
regression analysis without the 27G group and found that VW/BW still significantly correlated
with the week-4 average systolic pressure (figure 2(B)). The week-4 average systolic pressure








Table 1. Summary of cardiac hypertrophy and average hemodynamic parameters.
VW/ Total Total Total Total Total Total
Group BW Wk-4 SP Wk-4 DP Wk-4 pulse Wk-4 MAP Wk-4 HR Wk-4 RPP SP DP pulse MAP HR RPP
Sham 3.86 125.03 107.62 17.41 115.74 539.25 67 421.48 128.38 110.74 17.64 118.83 529.62 67 994.45
Sham 3.73 121.99 119.01 2.98 123.53 475.90 58 054.51 159.47 140.39 19.08 146.31 504.98 80 527.68
Sham 3.77 119.42 93.96 25.46 107.00 546.63 65 278.95 128.20 104.03 24.17 116.14 580.58 74 431.65
25G 4.09 138.71 112.30 26.41 124.59 580.62 80 536.48 134.91 106.94 27.96 120.55 516.53 69 682.21
25G 4.09 133.16 97.29 35.87 115.13 571.19 76 058.77 134.85 99.67 35.17 117.11 531.70 71 698.52
25G 4.17 143.60 132.34 11.27 137.49 454.89 65 323.61 158.57 147.66 10.90 152.41 448.86 71 173.94
25G 4.48 141.18 110.51 30.67 125.89 566.41 79 967.80 142.73 112.03 30.70 127.56 558.57 79 725.69
26G 4.94 148.99 106.25 42.74 127.18 576.52 85 892.97 140.12 103.85 36.27 121.88 571.05 80 015.87
26G 4.71 146.33 107.09 39.24 119.59 503.33 73 652.44 142.09 105.94 36.15 123.35 516.84 73 438.98
26G 4.55 135.37 102.51 32.86 118.93 506.98 68 630.93 137.84 105.58 32.26 121.78 539.16 74 319.23
26G 4.40 133.55 102.64 30.91 118.11 508.95 67 971.95 136.22 107.53 28.69 121.72 539.16 73 443.30
27G 6.13 187.67 129.23 58.44 155.21 576.52 108 196.60 169.15 127.46 41.69 145.89 538.31 91 053.94
27G 6.33 207.79 196.90 10.89 203.25 455.66 94 680.70 205.62 196.48 9.14 200.41 481.58 99 021.79
27G 5.28 149.42 128.62 20.80 136.51 487.03 72 771.79 144.79 124.63 20.16 132.79 476.55 68 997.33
VW/BW, ventricular weight/body weight (mg g−1);
SP, systolic pressure (mmHg);
DP, diastolic pressure (mmHg);
Pulse, pulse pressure (mmHg);
MAP, mean arterial pressure (mmHg);
HR, heart rate (beats min−1);
RPP, rate–pressure product (mmHg × beats min−1);
Wk: week.
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Figure 2. Correlation between cardiac hypertrophy and week-4 systolic pressure analyzed by
linear regression. (A) Correlation that includes all groups. (B) Correlation without the 27G group.
Table 2. Correlations between cardiac hypertrophy and hemodynamic parameters analyzed by
stepwise multiple regression.
VW/BW
Pearson correlation (r) P (1-tailed)
Wk-4 SP 0.951 0
Wk-4 DP 0.712 0.002
Wk-4 pulse 0.343 0.115
Wk-4 MAP 0.835 0
Wk-4 HR −0.123 0.337
Wk-4 RPP 0.833 0
Total SP 0.732 0.001
Total DP 0.545 0.022
Total pulse 0.081 0.392
Total MAP 0.64 0.007
Total HR −0.202 0.244
Total RPP 0.747 0.001
VW/BW, ventricular weight/body weight (mg g−1);
SP, systolic pressure (mmHg);
DP, diastolic pressure (mmHg);
pulse, pulse pressure (mmHg);
MAP, mean arterial pressure (mmHg);
HR, heart rate (beats min−1);
RPP, rate–pressure product (mmHg × beats min−1);
Wk: week.
Cardiac fibrosis correlates with cardiac hypertrophy better than with the systolic pressure. In
order to further investigate the relationship between cardiac fibrosis and hypertrophy or POL,
we stained the ventricle slices with Mason-trichrome and quantified the fibrosis percentage.
As shown by the representative straining (figure 3), greater constriction caused more fibrosis
in the hearts. Cardiac fibrosis significantly correlated with the cardiac size (VW/BW), but the
correlation with the week-4 average systolic pressure was not significant (table 3). Stepwise
multiple regression determined VW/BW as the better predictor of cardiac fibrosis.
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Figure 3. Cardiac fibrosis with aortic constrictions. Representative trichrome-stained transverse
sections of left ventricles from sham-operated mice and mice with abdominal aortic constrictions.
The bar indicates 100 µm.
(This figure is in colour only in the electronic version)
Table 3. Correlations between cardiac fibrosis, cardiac hypertrophy and systolic pressure analyzed
by stepwise multiple regression.
Cardiac fibrosis (%)
Pearson correlation (r) P (1-tailed)
VW/BW 0.59 0.013
Wk-4 SP 0.381 0.089
VW/BW, ventricular weight/body weight (mg g−1);
SP, systolic pressure (mmHg).
Cardiac gene expression correlates with cardiac hypertrophy and systolic pressure. An
altered cardiac gene expression program is one of the characteristics of cardiac hypertrophy,
particularly that induced by POL (Schoenfeld et al 1998, Wagner et al 2004). We used RT-
QPCR to measure some of these expression levels in the ventricles with sham operation or
aortic constriction using 25G, 26G, or 27G needles, and correlated them with both VW/BW
and week-4 systolic pressure. Expression of ANP (a ventricular embryonic gene), Sk-Actin
(a cytoskeletal function related gene) and Coll III (one of the genes that are important for
controlling collagen deposition) significantly increased with aortic constriction (data not
shown). The expression of PLBN, which is important in calcium handling, decreased with
aortic constriction (data not shown). All of these data are consistent with previous reports
(Schoenfeld et al 1998, Wagner et al 2004). Normal adult’s hearts have a high expression
of α-MHC and low β-MHC level, but this is reversed in POL-induced cardiac hypertrophy
(Schoenfeld et al 1998, Wagner et al 2004). The expression of α-MHC decreased and that
of β-MHC increased with aortic constriction (data not shown), also consistent with previous
reports.
The expression of all six genes that we examined significantly correlated with both
VW/BW and week-4 systolic pressure (table 4). For the ANP and Sk-Actin expression, the
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Table 4. Correlations between cardiac gene expression and cardiac hypertrophy and systolic
pressure analyzed by stepwise multiple regression.
VW/BW wk4 SP
Pearson P Pearson P
correlation (r) (1-tailed) correlation (r) (1-tailed)
ANPa 0.748 0.001 0.857 0
Sk-Actina 0.731 0.001 0.784 0
α-MHCa −0.684 0.003 −0.554 0.02
β-MHCa 0.746 0.001 0.717 0.002
PLBNa −0.777 0.001 −0.668 0.005
Coll-IIIa 0.767 0.001 0.615 0.01
VW/BW, ventricular weight/body weight (mg g−1);
SP, systolic pressure (mmHg);
ANP, atrial natriuretic peptide; Sk-Actin, α skeletal actin;
α-MHC, α-myosin heavy chain; β-MHC, β-myosin heavy chain;
PLBN, phospholamban; Coll-III, type III collagen.
a Gene expression was measured by RT-QPCR and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an endogenous control.
correlation with the systolic pressure had higher significance and the week-4 systolic pressure
was determined as the predictor by stepwise multiple regression (table 4). However, VW/BW
was identified as the predictor for the gene expression of α-MHC, β-MHC, PLBN and Col III
(table 4).
Discussion
Cardiac hypertrophy, fibrosis and gene expression changes are all consequences of POL, a
commonly used animal model for cardiovascular research (Rockman et al 1991, De Windt et
al 2001, Asakawa et al 2002, McMullen et al 2003, Liao et al 2004, De Acetis et al 2005,
Takimoto et al 2005). However, their correlations with direct measurements of hemodynamic
parameters in POL have not been determined in conscious ambulatory mice. We demonstrated
that these measurements are technically feasible and give tight correlations with cardiac
hypertrophy.
Pulsatile arterial pressure in the arch of the aorta was measured via a radiotelemetry
device to assess POL in mice after abdominal aortic banding that produced different degrees
of constriction. Overall, the cardiac size correlated with the week-4 parameters better than
those of all measured periods, which is likely because the mice need 1–2 weeks to regain
their circadian rhythm after the telemetry implant surgeries (Leon et al 2004, Whitesall
et al 2004). Cardiac hypertrophy correlated best with the week-4 average systolic pressure
compared with other hemodynamic parameters such as diastolic pressure, MAP and rate-
pressure product, suggesting that systolic pressure is the most important determinant of the
cardiac size. This finding is consistent with studies in hypertensive human subjects (Lekakis
et al 2004, Libhaber et al 2005) that showed cardiac hypertrophy correlated with systolic
pressure more significantly.
Previously, Rockman et al measured the degree of constriction (pressure gradient) in
anesthetized mice at the end of POL (Esposito et al 2002). The radiotelemetry method
allowed the current study to monitor the hemodynamic parameters after POL in conscious
mice continuously, which would give more accurate measurements. In addition, the evaluation
of the degree of constriction in anesthetized animals cannot account for compensatory changes
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in conscious animals such as changes in vascular resistance or cardiac function that may
influence the final POL. For example, a drug that lowers the blood pressure or changes the
cardiac function would be expected to alter POL but would have no effect on the degree of
constriction. However, the real-time measurement demonstrated in our study will be able
to detect these POL changes. In addition to control for degree of constriction, our model
will distinguish between primary effects on hearts and effects secondary to changes in the
degree of POL when using manipulations that can affect both blood pressure and cardiac
myocytes directly. For instance, Asakawa et al used POL model to investigate the effects
of thiazolidinediones on cardiac hypertrophy (Asakawa et al 2002). It is well known that
thiazolidinediones (Diep et al 2002, Atkins et al 2005) can decrease blood pressure, which
makes it unclear if the inhibitory effects observed were because of decreased pressure or
intrinsic effects on the hearts. In order to further address the possibly direct effects of these
compounds on cardiac hypertrophy, pressure monitoring and correlation to cardiac size would
be necessary.
Cardiac fibrosis is a major characteristic of cardiac remodeling in pathological
hypertrophy, leading to cardiac dysfunction and failure (Boluyt et al 1994, Heling et al
2000, Kuwahara et al 2002). In this POL-induced cardiac hypertrophy model fibrosis is
correlated with the cardiac size but not the blood pressure. One explanation for this is that
pressure change is likely not the only factor that affects cardiac fibrosis. Other factors such
as inflammation are involved in the cardiac fibrosis process (Nicoletti and Michel 1999,
Kuwahara et al 2004, Ogata et al 2004) and inflammation has been observed in hypertensive
animal models including the POL model (Nicoletti and Michel 1999, Kuwahara et al 2004,
Ogata et al 2004). Further analyzing the correlation between inflammation and fibrosis in this
model would lead to more precise explanation on this aspect.
POL-induced cardiac hypertrophy is usually associated with a characteristic pattern of the
cardiac gene expression (Schoenfeld et al 1998, Hoshijima and Chien 2002, Wagner et al 2004).
This cardiac gene program, including changes in the expression of genes related to growth and
metabolism as well as reactivation of fetal genes, may ultimately trigger pathological changes
in the myocardium and cause irreversible cardiac dysfunction (Hoshijima and Chien 2002).
The significant correlations between the cardiac gene expression and both cardiac size and
systolic pressure further demonstrate the accuracy of pressure monitoring to reflect cardiac
hypertrophy in our model. For some cardiac genes (ANP and Sk-Actin) their expression
correlated with POL better than with the cardiac size, indicating that these genes’ expression
is dominantly controlled by pressure changes. The expression of other cardiac genes (α-MHC,
β-MHC, PLBN and Coll III) correlated with the cardiac size better than with POL, suggesting
that other factors such as inflammation could also contribute to the changes in the cardiac gene
expression.
In summary, our data provided more insights about the correlations between blood pressure
and other hemodynamic parameters, cardiac hypertrophy, cardiac fibrosis and cardiac gene
expression, and demonstrated that direct real-time pressure monitoring is a practical method
to extend the usefulness of POL models to manipulations that can affect both blood pressure
and myocyte intrinsic responses.
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